(23) on the timing of radiotherapy for advanced non oligometastatic NSCLC patients with EGFR mutations treated with EGFR-TKI combined with SBRT showed that primary tumor SBRT treatment at EGFR-TKI maximum remission was significantly better than primary tumor SBRT treatment after oligo progression, significantly improving PFS (22.3 months vs 12.9 months, P=0.0031), and there was no significant difference in median OS (46.6 months vs 51.3 months, P=0.54), There is no toxicity level 3 or above, and the safety is controllable. This evidence concerns the gene EGFR and non-small cell lung carcinoma.